CEO FOR OCCLUNOVA

A novel device to close the left atrial appendage which significantly reduces the risk of stroke in patients with atrial fibrillation

Entrepreneurial CEO for OccluNova

Occlunova is a venture that develops a novel minimally-invasive device to close the left atrial appendage and significantly reduce the risk of stroke in patients with atrial fibrillation.

The invention

A catheter-based implantable device to occlude the left atrial appendage, a part of the heart responsible for increased stroke risk in atrial fibrillation patients. This technology improves upon current practice by providing a solution that more completely fits to various heart anatomies, offers a complete occlusion of the left atrial appendage with lower risk of heart tissue damage and device-related clotting, and leads to faster and less complicated procedures.

The position of CEO

The CEO will be responsible for developing and executing the overall business strategy, actively supported by NLC The Healthtech Venture Builder and partnering with the inventor team of a major medical device manufacturer and other strategic partners.

Responsibilities include:

• Proven experience with dilutive and non-dilutive fundraising
• Navigate and engage with relevant network of interventional cardiologists
• Guide medical devices product development
• Gain regulatory approval

CEO competencies and track record

You are highly motivated to make an impact on patients, have commercial success and are often described as:

• Entrepreneurial
• A connector with strong networking and influencing ability at all levels of seniority
• Excellent communication skills, including presentation and negotiation skills
• Fundraising experience, both dilutive and non-dilutive
• Excellent network of interventional cardiologists
• Based in Minneapolis

The opportunity

We offer the unique opportunity to an entrepreneur or executive with entrepreneurial ambition to come on board in a highly promising venture. The participation package includes:

• Equity-based remuneration.
• Cash compensation tied to successful funding of the company
• The opportunity to Co-fund at a favorable valuation.
• Access to the expertise and network of the entire NLC ecosystem including the use of NLC Venture Services.
• Sparring and support from your Venture Partner and the dozens of CEO's leading our other (80+) ventures.

Last but not least: You should want to lead this venture because this device would improve the standard of care in a significant and growing patient population with atrial fibrillation.